|
|
|
Insider
Information: |
Eshelman Fredric N |
Relationship: |
10% Owner |
City: |
Wilmington |
State: |
NC |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
8,151,654 |
|
Indirect Shares
|
3,933,809 |
|
|
Direct
Value |
$86,486,376 |
|
|
Indirect Value
|
$13,868,647 |
|
|
Total
Shares |
12,085,463 |
|
|
Total
Value |
$100,355,023 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
7
|
3
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
7
|
3
|
|
|
|
Gain/Loss Ratio : |
-7.0
|
-3.0
|
Percentage
Gain/Loss : |
-45.7%
|
-43.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmaceutical Product Developme... |
PPDI |
Executive Chairman, Di... |
2011-12-05 |
0 |
2011-12-05 |
0 |
Premium* |
|
Furiex Pharmaceuticals, Inc. |
FURX |
Director, 10% Owner |
2014-07-02 |
0 |
2014-07-02 |
0 |
Premium* |
|
Bausch Health Companies Inc |
BHC |
Director |
2017-05-05 |
38,298 |
2016-03-11 |
0 |
Premium* |
|
G1 Therapeutics Inc |
GTHX |
Director, 10% Owner |
2017-11-13 |
250,000 |
2017-11-13 |
3,439,151 |
Premium* |
|
Eyenovia Inc |
EYEN |
Director |
2020-09-11 |
1,292,787 |
2020-09-11 |
319,085 |
Premium* |
|
Liquidia Technologies Inc |
LQDA |
10% Owner |
2020-11-25 |
6,570,569 |
2020-11-25 |
175,573 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-20 |
4 |
S |
$59.96 |
$9,185,899 |
D/D |
(153,000) |
5,209,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.51 |
$3,401,213 |
D/D |
(56,989) |
5,152,274 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.40 |
$4,655,153 |
D/D |
(77,788) |
5,074,486 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.37 |
$41,500 |
D/D |
(699) |
5,060,053 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.26 |
$2,325,274 |
D/D |
(38,976) |
5,034,811 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-22 |
4 |
S |
$59.03 |
$3,250,299 |
D/D |
(54,601) |
4,980,210 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-22 |
4 |
S |
$59.02 |
$1,076,796 |
D/D |
(17,947) |
4,962,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2008-05-21 |
4 |
S |
$43.53 |
$609,718 |
D/D |
(14,000) |
8,004,626 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2008-05-19 |
4 |
S |
$42.83 |
$1,720,793 |
D/D |
(40,000) |
8,114,626 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2008-05-20 |
4 |
S |
$42.63 |
$2,785,830 |
D/D |
(65,220) |
8,018,626 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2008-05-20 |
4 |
S |
$42.52 |
$1,310,091 |
D/D |
(30,780) |
8,083,846 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.99 |
$156,255 |
D/D |
(4,004) |
8,350,626 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.69 |
$1,611,552 |
D/D |
(41,496) |
8,354,630 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.37 |
$824,675 |
D/D |
(21,400) |
8,396,126 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-02 |
4 |
S |
$38.33 |
$1,361,527 |
D/D |
(35,433) |
8,433,960 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-02 |
4 |
S |
$38.01 |
$1,831,020 |
D/D |
(47,900) |
8,469,393 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$37.99 |
$627,749 |
D/D |
(16,434) |
8,417,526 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-01 |
4 |
S |
$37.27 |
$7,454 |
D/D |
(200) |
8,600,627 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-01 |
4 |
S |
$36.91 |
$789,374 |
D/D |
(21,341) |
8,600,827 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2006-05-15 |
4 |
S |
$36.88 |
$2,016,198 |
D/D |
(54,575) |
9,577,526 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-18 |
4 |
S |
$36.86 |
$1,028,407 |
D/D |
(27,852) |
8,517,293 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2006-05-16 |
4 |
S |
$36.69 |
$447,470 |
D/D |
(12,180) |
9,430,526 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-19 |
4 |
S |
$36.58 |
$3,658 |
D/D |
(100) |
8,600,227 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-18 |
4 |
S |
$36.56 |
$2,036,971 |
D/D |
(55,382) |
8,545,145 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2006-05-15 |
4 |
S |
$36.45 |
$7,278,096 |
D/D |
(198,425) |
9,632,101 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|